| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Renal Cell | 116 | 2024 | 3217 | 8.970 |
Why?
|
| Kidney Neoplasms | 109 | 2024 | 4312 | 7.430 |
Why?
|
| Carbonic Anhydrases | 9 | 2024 | 109 | 2.020 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 12 | 2024 | 307 | 1.270 |
Why?
|
| Prostate | 16 | 2022 | 1793 | 1.240 |
Why?
|
| Tumor Suppressor Proteins | 23 | 2021 | 2804 | 1.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 14 | 2024 | 1090 | 1.150 |
Why?
|
| Antigens, Neoplasm | 11 | 2024 | 1999 | 1.130 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 11 | 2022 | 1137 | 0.940 |
Why?
|
| Endogenous Retroviruses | 2 | 2023 | 111 | 0.880 |
Why?
|
| Prostatic Neoplasms | 33 | 2024 | 11341 | 0.820 |
Why?
|
| Gene Expression Regulation, Neoplastic | 36 | 2024 | 8498 | 0.800 |
Why?
|
| Urologic Neoplasms | 5 | 2019 | 321 | 0.760 |
Why?
|
| Protein Kinase Inhibitors | 14 | 2022 | 5640 | 0.710 |
Why?
|
| Trans-Activators | 9 | 2015 | 2861 | 0.700 |
Why?
|
| Small Cell Lung Carcinoma | 5 | 2023 | 421 | 0.680 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 2019 | 800 | 0.640 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 5 | 2017 | 620 | 0.630 |
Why?
|
| Mutation | 31 | 2022 | 29950 | 0.600 |
Why?
|
| PTEN Phosphohydrolase | 18 | 2022 | 1115 | 0.600 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 6 | 2024 | 81 | 0.590 |
Why?
|
| Interleukin-2 | 6 | 2016 | 1890 | 0.580 |
Why?
|
| Anilides | 4 | 2022 | 409 | 0.560 |
Why?
|
| Viral Envelope Proteins | 1 | 2020 | 638 | 0.560 |
Why?
|
| Prognosis | 34 | 2024 | 29636 | 0.550 |
Why?
|
| Niacinamide | 8 | 2017 | 414 | 0.550 |
Why?
|
| Neoplasm Metastasis | 20 | 2019 | 4891 | 0.550 |
Why?
|
| TOR Serine-Threonine Kinases | 11 | 2020 | 2058 | 0.540 |
Why?
|
| Pyridines | 11 | 2022 | 2877 | 0.540 |
Why?
|
| Immunohistochemistry | 32 | 2021 | 11064 | 0.540 |
Why?
|
| Nephrectomy | 6 | 2024 | 1017 | 0.540 |
Why?
|
| Stem Cells | 7 | 2015 | 3525 | 0.530 |
Why?
|
| Phosphoproteins | 6 | 2013 | 2441 | 0.530 |
Why?
|
| Phenylurea Compounds | 8 | 2017 | 529 | 0.510 |
Why?
|
| Cell Proliferation | 20 | 2024 | 10434 | 0.500 |
Why?
|
| Genes, Tumor Suppressor | 12 | 2021 | 1056 | 0.490 |
Why?
|
| Benzenesulfonates | 6 | 2011 | 165 | 0.490 |
Why?
|
| Cell Line, Tumor | 43 | 2024 | 16905 | 0.480 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2022 | 11708 | 0.470 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2022 | 2927 | 0.470 |
Why?
|
| Antineoplastic Agents | 21 | 2020 | 13629 | 0.460 |
Why?
|
| Ubiquitin Thiolesterase | 5 | 2021 | 454 | 0.450 |
Why?
|
| Transcription Factors | 24 | 2023 | 12100 | 0.440 |
Why?
|
| Humans | 212 | 2024 | 760261 | 0.440 |
Why?
|
| Urinary Bladder Neoplasms | 6 | 2017 | 2277 | 0.430 |
Why?
|
| Gene Dosage | 5 | 2014 | 1218 | 0.420 |
Why?
|
| Carcinoma, Papillary | 3 | 2015 | 785 | 0.420 |
Why?
|
| Gene Expression Profiling | 20 | 2021 | 9388 | 0.410 |
Why?
|
| Immunotherapy | 11 | 2024 | 4637 | 0.410 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 1347 | 0.400 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2020 | 567 | 0.400 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 8 | 2024 | 319 | 0.390 |
Why?
|
| Mice | 74 | 2024 | 81216 | 0.390 |
Why?
|
| Angiogenesis Inhibitors | 8 | 2016 | 2047 | 0.390 |
Why?
|
| Neoplasm Proteins | 5 | 2019 | 3613 | 0.380 |
Why?
|
| Nuclear Proteins | 8 | 2020 | 5793 | 0.370 |
Why?
|
| Cell Transformation, Neoplastic | 12 | 2021 | 2823 | 0.370 |
Why?
|
| Indans | 3 | 2022 | 91 | 0.370 |
Why?
|
| Sulfonamides | 5 | 2017 | 1973 | 0.360 |
Why?
|
| DNA-Binding Proteins | 20 | 2021 | 9590 | 0.340 |
Why?
|
| Immunoenzyme Techniques | 7 | 2015 | 1705 | 0.340 |
Why?
|
| Animals | 90 | 2024 | 167940 | 0.330 |
Why?
|
| Male | 108 | 2024 | 359413 | 0.330 |
Why?
|
| Cell Lineage | 3 | 2013 | 2525 | 0.330 |
Why?
|
| CD8-Positive T-Lymphocytes | 8 | 2024 | 4554 | 0.330 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2010 | 148 | 0.330 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2009 | 151 | 0.320 |
Why?
|
| Receptors, KIR | 2 | 2020 | 113 | 0.310 |
Why?
|
| Sulfones | 3 | 2022 | 447 | 0.310 |
Why?
|
| Pyrimidines | 7 | 2022 | 3011 | 0.310 |
Why?
|
| Histone Demethylases | 6 | 2023 | 323 | 0.310 |
Why?
|
| Mammary Neoplasms, Experimental | 5 | 2012 | 501 | 0.300 |
Why?
|
| Tumor Microenvironment | 9 | 2024 | 3826 | 0.290 |
Why?
|
| Neoplasm Staging | 12 | 2024 | 11141 | 0.290 |
Why?
|
| Disease Models, Animal | 15 | 2024 | 18134 | 0.290 |
Why?
|
| Cell Differentiation | 11 | 2024 | 11480 | 0.290 |
Why?
|
| Signal Transduction | 26 | 2021 | 23363 | 0.280 |
Why?
|
| Female | 92 | 2024 | 391011 | 0.270 |
Why?
|
| Urothelium | 3 | 2016 | 277 | 0.270 |
Why?
|
| Adenoma | 3 | 2015 | 2148 | 0.270 |
Why?
|
| Pyrroles | 6 | 2017 | 1137 | 0.270 |
Why?
|
| T-Lymphocytes | 6 | 2024 | 10183 | 0.260 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2015 | 2052 | 0.260 |
Why?
|
| Indazoles | 6 | 2024 | 302 | 0.260 |
Why?
|
| Androgens | 5 | 2013 | 1289 | 0.250 |
Why?
|
| Retinoblastoma Protein | 3 | 2018 | 671 | 0.250 |
Why?
|
| Molecular Targeted Therapy | 9 | 2024 | 2805 | 0.250 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2008 | 377 | 0.240 |
Why?
|
| Epigenomics | 4 | 2024 | 936 | 0.240 |
Why?
|
| Cell Cycle Proteins | 7 | 2012 | 3448 | 0.240 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 4 | 2016 | 666 | 0.240 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2022 | 2866 | 0.240 |
Why?
|
| Lipogenesis | 2 | 2018 | 210 | 0.230 |
Why?
|
| Indoles | 6 | 2017 | 1830 | 0.230 |
Why?
|
| Epithelial Cells | 10 | 2009 | 3665 | 0.230 |
Why?
|
| Aged | 49 | 2024 | 168995 | 0.230 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2013 | 1346 | 0.230 |
Why?
|
| Membrane Proteins | 5 | 2014 | 7854 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2021 | 6545 | 0.220 |
Why?
|
| Middle Aged | 52 | 2024 | 220175 | 0.220 |
Why?
|
| Ubiquitin-Protein Ligases | 4 | 2018 | 1890 | 0.220 |
Why?
|
| Sirolimus | 6 | 2018 | 1548 | 0.220 |
Why?
|
| Adenocarcinoma | 10 | 2022 | 6310 | 0.220 |
Why?
|
| Mice, Nude | 13 | 2019 | 3605 | 0.210 |
Why?
|
| Butyrate Response Factor 1 | 1 | 2022 | 10 | 0.210 |
Why?
|
| Neoplasms | 12 | 2024 | 22066 | 0.210 |
Why?
|
| Survival Analysis | 9 | 2021 | 10185 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2018 | 5230 | 0.210 |
Why?
|
| Tankyrases | 1 | 2022 | 13 | 0.210 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2022 | 938 | 0.210 |
Why?
|
| Carcinoma | 4 | 2023 | 2334 | 0.200 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2019 | 859 | 0.200 |
Why?
|
| Survival Rate | 9 | 2020 | 12806 | 0.200 |
Why?
|
| DNA, Neoplasm | 4 | 2016 | 1745 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 8 | 2023 | 3483 | 0.190 |
Why?
|
| Treatment Outcome | 24 | 2024 | 64947 | 0.190 |
Why?
|
| Apoptosis | 13 | 2019 | 9497 | 0.190 |
Why?
|
| Loss of Heterozygosity | 2 | 2021 | 659 | 0.190 |
Why?
|
| Receptor, Notch2 | 1 | 2021 | 87 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2019 | 3584 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2016 | 2449 | 0.190 |
Why?
|
| Aged, 80 and over | 19 | 2024 | 58947 | 0.190 |
Why?
|
| Immunoglobulins | 2 | 2023 | 863 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 8 | 2013 | 6067 | 0.190 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2021 | 158 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2021 | 698 | 0.190 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2022 | 317 | 0.190 |
Why?
|
| Immune System Diseases | 1 | 2023 | 258 | 0.180 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2014 | 600 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2017 | 9274 | 0.180 |
Why?
|
| Sarcoma | 3 | 2023 | 1786 | 0.180 |
Why?
|
| Doxorubicin | 5 | 2014 | 2207 | 0.180 |
Why?
|
| Catheter Ablation | 7 | 2011 | 2755 | 0.180 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2014 | 412 | 0.180 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 3 | 2000 | 330 | 0.180 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 2 | 2019 | 174 | 0.180 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 2000 | 345 | 0.180 |
Why?
|
| Epithelium | 3 | 2015 | 1605 | 0.170 |
Why?
|
| Retinoblastoma-Binding Protein 2 | 1 | 2019 | 30 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2024 | 3531 | 0.170 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 1999 | 91 | 0.170 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2022 | 259 | 0.170 |
Why?
|
| Genome, Human | 5 | 2018 | 4416 | 0.170 |
Why?
|
| Amino Acid Transport System y+ | 2 | 2016 | 37 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2020 | 544 | 0.170 |
Why?
|
| 5'-Nucleotidase | 1 | 2020 | 161 | 0.170 |
Why?
|
| Lung Neoplasms | 6 | 2023 | 13249 | 0.170 |
Why?
|
| Aspartic Acid | 1 | 2002 | 576 | 0.170 |
Why?
|
| Neovascularization, Pathologic | 5 | 2016 | 2641 | 0.170 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2022 | 1591 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2013 | 4024 | 0.160 |
Why?
|
| Neuroendocrine Cells | 1 | 2019 | 62 | 0.160 |
Why?
|
| Disease-Free Survival | 8 | 2017 | 6830 | 0.160 |
Why?
|
| Genes, Immunoglobulin | 1 | 1999 | 287 | 0.160 |
Why?
|
| Receptor, Notch1 | 1 | 2021 | 495 | 0.160 |
Why?
|
| Rhabdoid Tumor | 1 | 2021 | 210 | 0.160 |
Why?
|
| Serine Proteases | 1 | 2018 | 50 | 0.160 |
Why?
|
| Lymphoma, B-Cell | 3 | 2000 | 935 | 0.160 |
Why?
|
| Cell Cycle | 6 | 2014 | 2937 | 0.160 |
Why?
|
| STAT3 Transcription Factor | 2 | 2015 | 877 | 0.160 |
Why?
|
| Ubiquitination | 2 | 2014 | 1010 | 0.160 |
Why?
|
| Triazines | 1 | 2020 | 310 | 0.150 |
Why?
|
| DNA Mutational Analysis | 3 | 2013 | 4109 | 0.150 |
Why?
|
| Oncogenes | 4 | 2023 | 1221 | 0.150 |
Why?
|
| DNA Copy Number Variations | 4 | 2023 | 2008 | 0.150 |
Why?
|
| Sterol Regulatory Element Binding Proteins | 1 | 2018 | 25 | 0.150 |
Why?
|
| RNA, Neoplasm | 3 | 2015 | 749 | 0.150 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2018 | 102 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2019 | 629 | 0.150 |
Why?
|
| Gene Rearrangement | 5 | 2011 | 1122 | 0.150 |
Why?
|
| Glutathione Peroxidase | 1 | 2019 | 256 | 0.150 |
Why?
|
| Foot Diseases | 1 | 1999 | 147 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2019 | 556 | 0.150 |
Why?
|
| Phosphorylation | 9 | 2016 | 8314 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2023 | 1151 | 0.150 |
Why?
|
| Adult | 33 | 2024 | 219847 | 0.150 |
Why?
|
| Kidney | 7 | 2019 | 7072 | 0.150 |
Why?
|
| Phenotype | 14 | 2023 | 16543 | 0.140 |
Why?
|
| Chromatin | 3 | 2023 | 2939 | 0.140 |
Why?
|
| Breast Neoplasms | 9 | 2022 | 21065 | 0.140 |
Why?
|
| Histone Code | 1 | 2018 | 157 | 0.140 |
Why?
|
| Protein Kinases | 4 | 2015 | 1612 | 0.140 |
Why?
|
| Liposomes | 2 | 2011 | 776 | 0.140 |
Why?
|
| Disease Progression | 12 | 2024 | 13505 | 0.140 |
Why?
|
| Nevus, Pigmented | 1 | 1999 | 221 | 0.140 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 2020 | 679 | 0.140 |
Why?
|
| Genomics | 8 | 2022 | 5790 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2019 | 346 | 0.140 |
Why?
|
| Receptors, Estrogen | 2 | 2002 | 2202 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2018 | 788 | 0.130 |
Why?
|
| Cytosine Deaminase | 1 | 2016 | 65 | 0.130 |
Why?
|
| Eccrine Glands | 1 | 1996 | 52 | 0.130 |
Why?
|
| Colorectal Neoplasms | 2 | 2013 | 6855 | 0.130 |
Why?
|
| Receptor, erbB-2 | 3 | 2012 | 2544 | 0.130 |
Why?
|
| Microsatellite Repeats | 1 | 2018 | 786 | 0.130 |
Why?
|
| Spin Labels | 3 | 2016 | 336 | 0.130 |
Why?
|
| Forkhead Transcription Factors | 4 | 2024 | 1613 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 9 | 2021 | 3618 | 0.130 |
Why?
|
| Cell Membrane | 2 | 2015 | 3683 | 0.130 |
Why?
|
| Activin Receptors, Type II | 1 | 2016 | 123 | 0.130 |
Why?
|
| Complementarity Determining Regions | 1 | 2016 | 149 | 0.130 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2015 | 376 | 0.130 |
Why?
|
| Mice, Transgenic | 10 | 2013 | 9531 | 0.130 |
Why?
|
| HMGB1 Protein | 1 | 2017 | 138 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 2 | 2017 | 1060 | 0.130 |
Why?
|
| Mice, Knockout | 11 | 2021 | 14396 | 0.130 |
Why?
|
| Enzyme Inhibitors | 6 | 2022 | 3726 | 0.130 |
Why?
|
| Brain Neoplasms | 3 | 2023 | 8984 | 0.120 |
Why?
|
| Neoplasm Transplantation | 7 | 2014 | 2014 | 0.120 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 39254 | 0.120 |
Why?
|
| Lymphocyte Subsets | 1 | 2016 | 310 | 0.120 |
Why?
|
| Chemokine CXCL12 | 1 | 2017 | 454 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 1146 | 0.120 |
Why?
|
| Angiomyolipoma | 1 | 2016 | 184 | 0.120 |
Why?
|
| Metaplasia | 2 | 2013 | 320 | 0.120 |
Why?
|
| Receptors, Notch | 1 | 2019 | 742 | 0.120 |
Why?
|
| Skin Neoplasms | 5 | 2004 | 5797 | 0.120 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2015 | 436 | 0.120 |
Why?
|
| src-Family Kinases | 2 | 2014 | 534 | 0.120 |
Why?
|
| Paracrine Communication | 1 | 2016 | 278 | 0.120 |
Why?
|
| Imidazoles | 4 | 2017 | 1178 | 0.120 |
Why?
|
| Proline | 1 | 2016 | 457 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 1442 | 0.120 |
Why?
|
| Paraffin Embedding | 3 | 2008 | 302 | 0.120 |
Why?
|
| Elafin | 1 | 2014 | 31 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 4 | 2015 | 9196 | 0.120 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2014 | 63 | 0.120 |
Why?
|
| Pyrazines | 1 | 2020 | 1200 | 0.120 |
Why?
|
| G-Protein-Coupled Receptor Kinase 3 | 1 | 2014 | 6 | 0.120 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2016 | 203 | 0.120 |
Why?
|
| Deoxycytidine | 2 | 2017 | 872 | 0.120 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2014 | 104 | 0.120 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2012 | 121 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 1723 | 0.120 |
Why?
|
| Leukemia | 1 | 2022 | 1522 | 0.110 |
Why?
|
| Enzyme Activators | 1 | 2014 | 57 | 0.110 |
Why?
|
| Immunity | 2 | 2018 | 998 | 0.110 |
Why?
|
| Cytological Techniques | 1 | 2015 | 218 | 0.110 |
Why?
|
| Fas Ligand Protein | 1 | 2014 | 215 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2015 | 311 | 0.110 |
Why?
|
| Protein Isoforms | 3 | 2014 | 1697 | 0.110 |
Why?
|
| GRB10 Adaptor Protein | 1 | 2013 | 23 | 0.110 |
Why?
|
| Retrospective Studies | 11 | 2024 | 80301 | 0.110 |
Why?
|
| Hand | 1 | 1999 | 903 | 0.110 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2013 | 72 | 0.110 |
Why?
|
| Myeloid Cells | 3 | 2023 | 821 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1 | 2 | 2019 | 193 | 0.110 |
Why?
|
| Models, Biological | 9 | 2016 | 9468 | 0.110 |
Why?
|
| Receptors, IgG | 1 | 2016 | 565 | 0.110 |
Why?
|
| Clinical Protocols | 1 | 2019 | 1439 | 0.110 |
Why?
|
| Protective Agents | 1 | 2014 | 150 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2013 | 2895 | 0.110 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 1388 | 0.110 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2013 | 126 | 0.110 |
Why?
|
| Pituitary Neoplasms | 2 | 2018 | 1313 | 0.110 |
Why?
|
| Cystectomy | 2 | 2017 | 697 | 0.100 |
Why?
|
| Cyclin D | 1 | 2012 | 72 | 0.100 |
Why?
|
| Brain Injuries | 2 | 2002 | 2044 | 0.100 |
Why?
|
| Sphingosine | 1 | 2015 | 308 | 0.100 |
Why?
|
| Genotype | 7 | 2018 | 12959 | 0.100 |
Why?
|
| SOX9 Transcription Factor | 1 | 2013 | 145 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2011 | 4494 | 0.100 |
Why?
|
| Odds Ratio | 3 | 2019 | 9712 | 0.100 |
Why?
|
| Lysophospholipids | 1 | 2015 | 339 | 0.100 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2018 | 781 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2021 | 10340 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2013 | 385 | 0.100 |
Why?
|
| Therapies, Investigational | 1 | 2013 | 111 | 0.100 |
Why?
|
| Carcinoma in Situ | 2 | 2017 | 796 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2014 | 473 | 0.100 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2014 | 428 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 3 | 2015 | 3800 | 0.100 |
Why?
|
| Citric Acid Cycle | 1 | 2013 | 230 | 0.100 |
Why?
|
| Cyclins | 1 | 2014 | 593 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 4 | 2018 | 4717 | 0.100 |
Why?
|
| Retinol-Binding Proteins, Cellular | 1 | 2011 | 12 | 0.100 |
Why?
|
| Qb-SNARE Proteins | 1 | 2011 | 34 | 0.100 |
Why?
|
| Receptors, Androgen | 4 | 2006 | 1075 | 0.100 |
Why?
|
| Cytodiagnosis | 1 | 2015 | 432 | 0.100 |
Why?
|
| Microtubule-Associated Proteins | 4 | 2001 | 1078 | 0.100 |
Why?
|
| Gene Knock-In Techniques | 1 | 2013 | 419 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2021 | 1589 | 0.100 |
Why?
|
| Cytoplasm | 3 | 2014 | 1518 | 0.100 |
Why?
|
| Cohort Studies | 8 | 2020 | 41317 | 0.100 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2011 | 397 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2000 | 2415 | 0.100 |
Why?
|
| Cysteine | 1 | 2016 | 897 | 0.100 |
Why?
|
| Cisplatin | 2 | 2014 | 1642 | 0.100 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2014 | 628 | 0.100 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 1651 | 0.090 |
Why?
|
| Perioperative Care | 1 | 2019 | 1032 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 6 | 2014 | 3618 | 0.090 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2011 | 152 | 0.090 |
Why?
|
| Cullin Proteins | 1 | 2012 | 178 | 0.090 |
Why?
|
| Genes, Neoplasm | 1 | 2013 | 370 | 0.090 |
Why?
|
| Transplantation, Heterologous | 4 | 2012 | 2378 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 6 | 2018 | 6131 | 0.090 |
Why?
|
| Mice, Inbred NOD | 2 | 2014 | 1837 | 0.090 |
Why?
|
| Androgen Antagonists | 3 | 2022 | 1439 | 0.090 |
Why?
|
| Histocytochemistry | 3 | 2011 | 693 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2011 | 286 | 0.090 |
Why?
|
| Biopsy | 3 | 2019 | 6775 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2022 | 2526 | 0.090 |
Why?
|
| Myocardial Stunning | 1 | 2010 | 66 | 0.090 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2010 | 81 | 0.090 |
Why?
|
| Quercetin | 1 | 2011 | 97 | 0.090 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 508 | 0.090 |
Why?
|
| F-Box Proteins | 1 | 2012 | 202 | 0.090 |
Why?
|
| Neoplasms, Experimental | 2 | 2006 | 1229 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 600 | 0.090 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2011 | 257 | 0.090 |
Why?
|
| HEK293 Cells | 5 | 2019 | 4264 | 0.090 |
Why?
|
| Polyomavirus | 1 | 2011 | 234 | 0.090 |
Why?
|
| Metabolomics | 1 | 2019 | 1626 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 3076 | 0.090 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2016 | 2776 | 0.090 |
Why?
|
| Mice, SCID | 2 | 2014 | 2627 | 0.090 |
Why?
|
| Smad4 Protein | 1 | 2011 | 191 | 0.090 |
Why?
|
| DNA Methylation | 4 | 2024 | 4374 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 3 | 2019 | 2811 | 0.080 |
Why?
|
| Myristic Acids | 1 | 2009 | 49 | 0.080 |
Why?
|
| Rats, Inbred F344 | 5 | 2010 | 825 | 0.080 |
Why?
|
| Genetic Heterogeneity | 3 | 2018 | 724 | 0.080 |
Why?
|
| Gene Deletion | 5 | 2020 | 2668 | 0.080 |
Why?
|
| Antineoplastic Protocols | 1 | 2009 | 50 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2011 | 225 | 0.080 |
Why?
|
| Epigenesis, Genetic | 3 | 2024 | 3758 | 0.080 |
Why?
|
| Oxygen | 2 | 2019 | 4189 | 0.080 |
Why?
|
| Computational Biology | 1 | 2021 | 3504 | 0.080 |
Why?
|
| Leiomyomatosis | 1 | 2009 | 69 | 0.080 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2013 | 633 | 0.080 |
Why?
|
| Down-Regulation | 4 | 2015 | 2918 | 0.080 |
Why?
|
| Brain Edema | 2 | 2006 | 603 | 0.080 |
Why?
|
| Quinolines | 2 | 2012 | 759 | 0.080 |
Why?
|
| STAT5 Transcription Factor | 1 | 2009 | 264 | 0.080 |
Why?
|
| Gene Expression | 2 | 2019 | 7592 | 0.080 |
Why?
|
| Aminopyridines | 3 | 2019 | 564 | 0.080 |
Why?
|
| Enzyme Activation | 5 | 2018 | 3604 | 0.080 |
Why?
|
| Oncogene Protein p21(ras) | 2 | 2014 | 68 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 1811 | 0.080 |
Why?
|
| Immunophenotyping | 2 | 2011 | 1870 | 0.080 |
Why?
|
| Cell Hypoxia | 3 | 2019 | 657 | 0.070 |
Why?
|
| Pyrazoles | 2 | 2022 | 1992 | 0.070 |
Why?
|
| RNA, Messenger | 8 | 2016 | 12762 | 0.070 |
Why?
|
| Up-Regulation | 5 | 2016 | 4127 | 0.070 |
Why?
|
| Skin Diseases | 1 | 1996 | 1089 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 9 | 2024 | 22025 | 0.070 |
Why?
|
| Tissue Banks | 1 | 2008 | 185 | 0.070 |
Why?
|
| Glioma | 1 | 2022 | 3420 | 0.070 |
Why?
|
| Virulence Factors | 1 | 2011 | 508 | 0.070 |
Why?
|
| Genetic Association Studies | 2 | 2016 | 2716 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2012 | 1246 | 0.070 |
Why?
|
| DNA Damage | 2 | 2015 | 2442 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2015 | 2612 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2016 | 2500 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2016 | 2536 | 0.070 |
Why?
|
| Keratin-15 | 1 | 2006 | 22 | 0.070 |
Why?
|
| Lymphoma, T-Cell | 2 | 2000 | 305 | 0.070 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1614 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 1602 | 0.070 |
Why?
|
| Prostatic Diseases | 1 | 2006 | 57 | 0.070 |
Why?
|
| Combined Modality Therapy | 7 | 2019 | 8551 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 3 | 2015 | 5784 | 0.070 |
Why?
|
| Repressor Proteins | 2 | 2022 | 2978 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2022 | 3421 | 0.070 |
Why?
|
| Intestinal Polyps | 2 | 2005 | 104 | 0.070 |
Why?
|
| Rats | 11 | 2013 | 23695 | 0.070 |
Why?
|
| beta-Galactosidase | 2 | 2005 | 575 | 0.070 |
Why?
|
| Cell Survival | 3 | 2014 | 5796 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2016 | 15766 | 0.070 |
Why?
|
| Arsenicals | 1 | 2006 | 117 | 0.070 |
Why?
|
| Gene Silencing | 2 | 2009 | 1511 | 0.060 |
Why?
|
| Paclitaxel | 2 | 2010 | 1738 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2021 | 995 | 0.060 |
Why?
|
| Quality Control | 1 | 2008 | 827 | 0.060 |
Why?
|
| Genetic Variation | 3 | 2016 | 6540 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 3 | 2020 | 2003 | 0.060 |
Why?
|
| Ki-67 Antigen | 4 | 2016 | 631 | 0.060 |
Why?
|
| Sarcoma, Experimental | 1 | 2005 | 118 | 0.060 |
Why?
|
| Lymphocyte Count | 2 | 2019 | 780 | 0.060 |
Why?
|
| Melanoma | 2 | 2019 | 5695 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 1344 | 0.060 |
Why?
|
| Tumor Burden | 3 | 2016 | 1897 | 0.060 |
Why?
|
| Clinical Trials as Topic | 4 | 2021 | 8058 | 0.060 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 378 | 0.060 |
Why?
|
| Arginase | 1 | 2005 | 80 | 0.060 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 11902 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 2424 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 2012 | 4938 | 0.060 |
Why?
|
| Transcription, Genetic | 5 | 2021 | 7593 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 2332 | 0.060 |
Why?
|
| Oxides | 1 | 2006 | 400 | 0.060 |
Why?
|
| In Situ Hybridization | 4 | 2001 | 1900 | 0.060 |
Why?
|
| Histones | 4 | 2019 | 2583 | 0.060 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2010 | 819 | 0.060 |
Why?
|
| Retroviridae | 2 | 2008 | 850 | 0.060 |
Why?
|
| Gene Transfer Techniques | 2 | 2002 | 1204 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2009 | 708 | 0.060 |
Why?
|
| Cell Line | 5 | 2019 | 15626 | 0.060 |
Why?
|
| Killer Cells, Natural | 3 | 2020 | 2204 | 0.060 |
Why?
|
| Calcium Channels | 1 | 2008 | 619 | 0.060 |
Why?
|
| Trauma Severity Indices | 1 | 2006 | 477 | 0.060 |
Why?
|
| Time Factors | 6 | 2017 | 40133 | 0.060 |
Why?
|
| Reference Values | 2 | 2002 | 4920 | 0.060 |
Why?
|
| Blotting, Western | 7 | 2010 | 5039 | 0.060 |
Why?
|
| Morpholines | 3 | 2016 | 583 | 0.060 |
Why?
|
| Cyclin-Dependent Kinases | 4 | 2001 | 656 | 0.060 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 2 | 2000 | 40 | 0.060 |
Why?
|
| Epidermal Growth Factor | 2 | 2008 | 695 | 0.060 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2006 | 412 | 0.060 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2008 | 854 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2005 | 459 | 0.050 |
Why?
|
| MicroRNAs | 3 | 2015 | 3784 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 15273 | 0.050 |
Why?
|
| Salicylanilides | 1 | 2022 | 15 | 0.050 |
Why?
|
| Methylation | 2 | 2019 | 1080 | 0.050 |
Why?
|
| Prospective Studies | 8 | 2022 | 54263 | 0.050 |
Why?
|
| Transplantation Chimera | 1 | 2005 | 595 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 3 | 2013 | 1617 | 0.050 |
Why?
|
| Genes, p53 | 2 | 2002 | 714 | 0.050 |
Why?
|
| Keratinocytes | 1 | 2006 | 792 | 0.050 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2002 | 59 | 0.050 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2002 | 90 | 0.050 |
Why?
|
| Antibodies | 2 | 2024 | 2424 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2023 | 177 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2018 | 3735 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2013 | 4002 | 0.050 |
Why?
|
| Orchiectomy | 3 | 2013 | 470 | 0.050 |
Why?
|
| Transfection | 4 | 2021 | 5782 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2009 | 3605 | 0.050 |
Why?
|
| Neurochemistry | 1 | 2002 | 29 | 0.050 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2021 | 17 | 0.050 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2002 | 84 | 0.050 |
Why?
|
| Dissection | 2 | 2002 | 298 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2014 | 3390 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 896 | 0.050 |
Why?
|
| Gene Amplification | 2 | 2010 | 1085 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2024 | 586 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2012 | 2522 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2010 | 1656 | 0.050 |
Why?
|
| Carcinoma, Embryonal | 1 | 2001 | 37 | 0.050 |
Why?
|
| Phenylthiohydantoin | 2 | 2013 | 203 | 0.050 |
Why?
|
| Cystadenoma, Serous | 1 | 2002 | 100 | 0.050 |
Why?
|
| Species Specificity | 2 | 2019 | 2413 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2018 | 1633 | 0.050 |
Why?
|
| Conserved Sequence | 2 | 2015 | 1168 | 0.050 |
Why?
|
| Benzimidazoles | 2 | 2019 | 858 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2016 | 6543 | 0.050 |
Why?
|
| Craniocerebral Trauma | 1 | 2006 | 491 | 0.050 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2005 | 586 | 0.050 |
Why?
|
| Angiotensin I | 1 | 2021 | 56 | 0.050 |
Why?
|
| Neutrophils | 3 | 2019 | 3770 | 0.050 |
Why?
|
| Benzoxazoles | 1 | 2022 | 89 | 0.050 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 4900 | 0.050 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2005 | 487 | 0.050 |
Why?
|
| Cell Death | 2 | 2010 | 1670 | 0.050 |
Why?
|
| Germ-Line Mutation | 2 | 2021 | 1843 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2019 | 1791 | 0.050 |
Why?
|
| Pathology, Clinical | 1 | 2024 | 375 | 0.050 |
Why?
|
| Isoenzymes | 3 | 2014 | 1690 | 0.050 |
Why?
|
| Cyclin D1 | 2 | 2014 | 453 | 0.050 |
Why?
|
| Insulin | 2 | 2008 | 6592 | 0.050 |
Why?
|
| cdc25 Phosphatases | 1 | 2000 | 60 | 0.050 |
Why?
|
| Estrogen Receptor beta | 1 | 2001 | 168 | 0.040 |
Why?
|
| Vinblastine | 2 | 2014 | 487 | 0.040 |
Why?
|
| Cell Division | 3 | 2002 | 4462 | 0.040 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2000 | 110 | 0.040 |
Why?
|
| Cell Adhesion | 2 | 2008 | 3096 | 0.040 |
Why?
|
| Pseudolymphoma | 1 | 2000 | 30 | 0.040 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2008 | 1007 | 0.040 |
Why?
|
| Young Adult | 5 | 2020 | 58673 | 0.040 |
Why?
|
| Endopeptidases | 1 | 2004 | 772 | 0.040 |
Why?
|
| Seminoma | 1 | 2001 | 134 | 0.040 |
Why?
|
| Blood Coagulation | 1 | 2006 | 1156 | 0.040 |
Why?
|
| Benzamides | 3 | 2013 | 1369 | 0.040 |
Why?
|
| Herpesvirus 8, Human | 2 | 2001 | 255 | 0.040 |
Why?
|
| Fibroblasts | 4 | 2018 | 4091 | 0.040 |
Why?
|
| Choline | 1 | 2002 | 513 | 0.040 |
Why?
|
| Retreatment | 1 | 2021 | 600 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2023 | 551 | 0.040 |
Why?
|
| Microvessels | 2 | 2015 | 572 | 0.040 |
Why?
|
| Cell Nucleus | 4 | 2000 | 2909 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2020 | 2473 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2021 | 361 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2015 | 17766 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 468 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2020 | 375 | 0.040 |
Why?
|
| Kynurenine | 1 | 2019 | 140 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2022 | 354 | 0.040 |
Why?
|
| Macrophages | 3 | 2021 | 5745 | 0.040 |
Why?
|
| Staining and Labeling | 2 | 2015 | 1090 | 0.040 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1999 | 217 | 0.040 |
Why?
|
| Lymphocytosis | 1 | 1999 | 119 | 0.040 |
Why?
|
| Genome-Wide Association Study | 3 | 2018 | 12602 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2006 | 4573 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 17628 | 0.040 |
Why?
|
| Proteins | 2 | 2010 | 6030 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 3774 | 0.040 |
Why?
|
| Heterozygote | 2 | 2021 | 2797 | 0.040 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2000 | 414 | 0.040 |
Why?
|
| Canada | 1 | 2024 | 2128 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2000 | 334 | 0.040 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2000 | 431 | 0.040 |
Why?
|
| DNA Primers | 2 | 2000 | 2819 | 0.040 |
Why?
|
| Mycosis Fungoides | 1 | 2000 | 167 | 0.040 |
Why?
|
| Chromosome Aberrations | 2 | 2015 | 1767 | 0.040 |
Why?
|
| Risk Factors | 8 | 2022 | 74269 | 0.040 |
Why?
|
| Ligands | 2 | 2016 | 3277 | 0.040 |
Why?
|
| B-Lymphocyte Subsets | 1 | 1999 | 241 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 558 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2020 | 534 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2019 | 271 | 0.040 |
Why?
|
| Alleles | 3 | 2018 | 6900 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2015 | 2698 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2000 | 1765 | 0.040 |
Why?
|
| Mice, Mutant Strains | 3 | 2010 | 1760 | 0.040 |
Why?
|
| Genes, Retinoblastoma | 1 | 2018 | 125 | 0.040 |
Why?
|
| Nitriles | 2 | 2013 | 955 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2021 | 850 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2020 | 1314 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 2218 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2010 | 1408 | 0.040 |
Why?
|
| Diagnosis, Differential | 6 | 2015 | 12968 | 0.040 |
Why?
|
| Tryptophan | 1 | 2019 | 480 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2016 | 10829 | 0.040 |
Why?
|
| Chromosome Segregation | 1 | 2018 | 233 | 0.040 |
Why?
|
| Administration, Intravesical | 1 | 2017 | 92 | 0.040 |
Why?
|
| Protein Binding | 3 | 2015 | 9336 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 1999 | 736 | 0.040 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2017 | 38 | 0.040 |
Why?
|
| Transcriptional Activation | 3 | 2010 | 1755 | 0.040 |
Why?
|
| RNA Interference | 2 | 2019 | 2846 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2014 | 36247 | 0.040 |
Why?
|
| Heart Septal Defects | 1 | 2018 | 191 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2008 | 3731 | 0.030 |
Why?
|
| Triazoles | 1 | 2022 | 904 | 0.030 |
Why?
|
| Melanins | 1 | 1999 | 291 | 0.030 |
Why?
|
| Hydroxylation | 1 | 2016 | 137 | 0.030 |
Why?
|
| Testosterone | 2 | 2012 | 2469 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2020 | 1577 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 1344 | 0.030 |
Why?
|
| Analysis of Variance | 3 | 2010 | 6242 | 0.030 |
Why?
|
| Glucose | 1 | 2008 | 4361 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2023 | 1266 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 6226 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2022 | 927 | 0.030 |
Why?
|
| Clone Cells | 1 | 1999 | 1663 | 0.030 |
Why?
|
| Creatinine | 1 | 2002 | 1906 | 0.030 |
Why?
|
| Tissue Embedding | 1 | 2015 | 42 | 0.030 |
Why?
|
| Benzylamines | 1 | 2017 | 248 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 803 | 0.030 |
Why?
|
| Erythema | 1 | 1997 | 262 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 2017 | 247 | 0.030 |
Why?
|
| Binding Sites | 2 | 2015 | 6050 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2020 | 1446 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2016 | 162 | 0.030 |
Why?
|
| Integrases | 1 | 2018 | 516 | 0.030 |
Why?
|
| Melanocytes | 1 | 1999 | 512 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 1387 | 0.030 |
Why?
|
| Perfusion | 2 | 2011 | 1376 | 0.030 |
Why?
|
| Base Sequence | 2 | 2013 | 12447 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2001 | 955 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2002 | 941 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 2651 | 0.030 |
Why?
|
| Chimera | 1 | 2016 | 453 | 0.030 |
Why?
|
| Proto-Oncogene Protein c-ets-2 | 1 | 2014 | 15 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2001 | 2195 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 3526 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 2001 | 800 | 0.030 |
Why?
|
| Germ Cells | 1 | 2018 | 635 | 0.030 |
Why?
|
| Granzymes | 1 | 2016 | 276 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2020 | 854 | 0.030 |
Why?
|
| Single-Chain Antibodies | 1 | 2015 | 111 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2020 | 1254 | 0.030 |
Why?
|
| Transgenes | 1 | 2018 | 1006 | 0.030 |
Why?
|
| Immunity, Innate | 2 | 2017 | 3046 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2014 | 2945 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 1 | 2014 | 19 | 0.030 |
Why?
|
| Cytidine Deaminase | 1 | 2016 | 245 | 0.030 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2016 | 280 | 0.030 |
Why?
|
| Multigene Family | 2 | 2010 | 1079 | 0.030 |
Why?
|
| Filgrastim | 1 | 2014 | 132 | 0.030 |
Why?
|
| BCG Vaccine | 1 | 2017 | 371 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2017 | 13456 | 0.030 |
Why?
|
| Adenoviruses, Human | 1 | 1996 | 255 | 0.030 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2015 | 303 | 0.030 |
Why?
|
| Barrett Esophagus | 1 | 1998 | 490 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2014 | 188 | 0.030 |
Why?
|
| Multiprotein Complexes | 2 | 2010 | 1120 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 652 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2006 | 3023 | 0.030 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 302 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2018 | 963 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2014 | 402 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 1892 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 630 | 0.030 |
Why?
|
| Genes, Lethal | 1 | 2013 | 225 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2000 | 1017 | 0.030 |
Why?
|
| Cell Communication | 2 | 2012 | 1642 | 0.030 |
Why?
|
| Liver | 2 | 2008 | 7512 | 0.030 |
Why?
|
| RNA | 3 | 2014 | 2721 | 0.030 |
Why?
|
| Pyruvic Acid | 1 | 2014 | 195 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2013 | 202 | 0.030 |
Why?
|
| RNA, Small Interfering | 3 | 2009 | 3443 | 0.030 |
Why?
|
| ROC Curve | 1 | 2021 | 3568 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2014 | 389 | 0.030 |
Why?
|
| Hyperplasia | 1 | 1996 | 1158 | 0.030 |
Why?
|
| Castration | 1 | 2012 | 153 | 0.030 |
Why?
|
| Adolescent | 4 | 2018 | 87747 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2019 | 1297 | 0.030 |
Why?
|
| Breast | 1 | 2002 | 1980 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 801 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 728 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 3 | 2001 | 649 | 0.030 |
Why?
|
| Piperazines | 2 | 2019 | 2520 | 0.030 |
Why?
|
| beta Catenin | 2 | 2011 | 1043 | 0.030 |
Why?
|
| Research Design | 1 | 2008 | 6181 | 0.030 |
Why?
|
| Thrombospondin 1 | 1 | 2014 | 257 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 551 | 0.030 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2012 | 45 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1999 | 1378 | 0.020 |
Why?
|
| Immunoblotting | 2 | 2009 | 1649 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1996 | 12281 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2009 | 1173 | 0.020 |
Why?
|
| Mesothelioma | 1 | 1998 | 806 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2014 | 635 | 0.020 |
Why?
|
| Glomus Tumor | 1 | 2012 | 62 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 724 | 0.020 |
Why?
|
| Cyclin E | 1 | 2012 | 157 | 0.020 |
Why?
|
| Lymphoma | 1 | 2001 | 1899 | 0.020 |
Why?
|
| Exons | 2 | 2011 | 2391 | 0.020 |
Why?
|
| Protein Engineering | 1 | 2015 | 541 | 0.020 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2011 | 41 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2023 | 2321 | 0.020 |
Why?
|
| Keratins | 2 | 2003 | 497 | 0.020 |
Why?
|
| Homozygote | 1 | 2016 | 1786 | 0.020 |
Why?
|
| Endonucleases | 1 | 2014 | 370 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2012 | 256 | 0.020 |
Why?
|
| Immune System | 1 | 2016 | 795 | 0.020 |
Why?
|
| CpG Islands | 1 | 2015 | 1221 | 0.020 |
Why?
|
| Genes, ras | 2 | 2004 | 654 | 0.020 |
Why?
|
| Endocytosis | 1 | 2015 | 960 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2017 | 1166 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2013 | 321 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2016 | 1166 | 0.020 |
Why?
|
| New York | 1 | 2013 | 874 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2016 | 1369 | 0.020 |
Why?
|
| Myocardium | 2 | 2010 | 4688 | 0.020 |
Why?
|
| Iron | 1 | 2019 | 1786 | 0.020 |
Why?
|
| Necrosis | 2 | 2005 | 1612 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2019 | 1711 | 0.020 |
Why?
|
| Precipitin Tests | 2 | 2001 | 815 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 4923 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2008 | 18968 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 1975 | 0.020 |
Why?
|
| California | 1 | 2014 | 1416 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2011 | 751 | 0.020 |
Why?
|
| Deoxyguanosine | 1 | 2010 | 92 | 0.020 |
Why?
|
| Atrophy | 2 | 2006 | 1625 | 0.020 |
Why?
|
| Subcellular Fractions | 2 | 2002 | 532 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2016 | 1739 | 0.020 |
Why?
|
| S Phase | 2 | 2000 | 422 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 8945 | 0.020 |
Why?
|
| Rabbits | 2 | 2006 | 4773 | 0.020 |
Why?
|
| Mitochondria | 2 | 2014 | 3598 | 0.020 |
Why?
|
| Penetrance | 1 | 2011 | 388 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2000 | 2877 | 0.020 |
Why?
|
| Osteopontin | 1 | 2011 | 302 | 0.020 |
Why?
|
| Aldehydes | 1 | 2010 | 171 | 0.020 |
Why?
|
| Genes, myc | 1 | 2010 | 395 | 0.020 |
Why?
|
| Fumarate Hydratase | 1 | 2009 | 52 | 0.020 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 381 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2009 | 191 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2009 | 163 | 0.020 |
Why?
|
| Incidence | 2 | 2022 | 21378 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2009 | 310 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2015 | 1430 | 0.020 |
Why?
|
| Cytokines | 1 | 2023 | 7345 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 12532 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2010 | 264 | 0.020 |
Why?
|
| Exudates and Transudates | 2 | 1999 | 175 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 1188 | 0.020 |
Why?
|
| Sex Factors | 2 | 2014 | 10530 | 0.020 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 4739 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2010 | 413 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2021 | 5120 | 0.020 |
Why?
|
| Telomerase | 2 | 2004 | 747 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2009 | 507 | 0.020 |
Why?
|
| Norway | 1 | 2009 | 497 | 0.020 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2008 | 89 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2013 | 1667 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2011 | 532 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 730 | 0.020 |
Why?
|
| Algorithms | 1 | 2008 | 13967 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2002 | 14656 | 0.020 |
Why?
|
| Methotrexate | 1 | 2014 | 1717 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2013 | 933 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 2178 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 2646 | 0.020 |
Why?
|
| Quality of Life | 2 | 2019 | 13300 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 795 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2014 | 3969 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5201 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 1996 | 3378 | 0.020 |
Why?
|
| Sweden | 1 | 2009 | 1381 | 0.020 |
Why?
|
| Virginia | 1 | 2006 | 116 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 1740 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2017 | 2093 | 0.020 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2006 | 239 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 2138 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 3105 | 0.020 |
Why?
|
| Dihydrotestosterone | 1 | 2006 | 195 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2011 | 840 | 0.020 |
Why?
|
| Child | 3 | 2018 | 79758 | 0.020 |
Why?
|
| Tyrosine | 1 | 2010 | 1440 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 384 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2006 | 282 | 0.020 |
Why?
|
| Echocardiography | 1 | 2018 | 4980 | 0.020 |
Why?
|
| Ornithine | 1 | 2005 | 79 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2017 | 8018 | 0.020 |
Why?
|
| Cell Polarity | 1 | 2008 | 638 | 0.020 |
Why?
|
| DNA Repair | 1 | 2014 | 2039 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 20484 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2009 | 5873 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2022 | 12901 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2005 | 278 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 616 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2014 | 5429 | 0.010 |
Why?
|
| Glucose Intolerance | 1 | 2008 | 579 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2009 | 2295 | 0.010 |
Why?
|
| United States | 1 | 2012 | 72363 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2002 | 5333 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2015 | 3491 | 0.010 |
Why?
|
| Extracellular Fluid | 1 | 2005 | 165 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 1553 | 0.010 |
Why?
|
| Age Distribution | 1 | 2009 | 2893 | 0.010 |
Why?
|
| Consensus | 1 | 2013 | 3106 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2010 | 1335 | 0.010 |
Why?
|
| Interferons | 1 | 2007 | 705 | 0.010 |
Why?
|
| Cell Movement | 1 | 2015 | 5206 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 1956 | 0.010 |
Why?
|
| Radiography | 1 | 2014 | 6965 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 2004 | 534 | 0.010 |
Why?
|
| Age Factors | 2 | 2010 | 18415 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 1490 | 0.010 |
Why?
|
| Syndrome | 1 | 2009 | 3278 | 0.010 |
Why?
|
| Sodium-Potassium-Chloride Symporters | 1 | 2002 | 104 | 0.010 |
Why?
|
| Age of Onset | 1 | 2009 | 3302 | 0.010 |
Why?
|
| Contrast Media | 1 | 2015 | 5301 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2002 | 283 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2002 | 135 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 2852 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2010 | 2486 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2005 | 789 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 548 | 0.010 |
Why?
|
| Arginine | 1 | 2005 | 934 | 0.010 |
Why?
|
| Mice, Inbred CBA | 1 | 2002 | 436 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2002 | 522 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2005 | 2262 | 0.010 |
Why?
|
| Genes, abl | 1 | 2000 | 69 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2005 | 1755 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 2528 | 0.010 |
Why?
|
| Flutamide | 1 | 2001 | 95 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2013 | 3903 | 0.010 |
Why?
|
| Chromones | 1 | 2000 | 150 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2000 | 189 | 0.010 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 2000 | 7 | 0.010 |
Why?
|
| Cycloheximide | 1 | 2000 | 343 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 666 | 0.010 |
Why?
|
| Ligases | 1 | 2002 | 332 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 871 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 749 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2000 | 183 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 2000 | 385 | 0.010 |
Why?
|
| Forecasting | 1 | 2009 | 2931 | 0.010 |
Why?
|
| Leukemia, Lymphoid | 1 | 2000 | 309 | 0.010 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2001 | 278 | 0.010 |
Why?
|
| G1 Phase | 1 | 2001 | 403 | 0.010 |
Why?
|
| Obesity | 1 | 2022 | 12915 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2000 | 201 | 0.010 |
Why?
|
| Half-Life | 1 | 2000 | 652 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2000 | 429 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 674 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2002 | 839 | 0.010 |
Why?
|
| Linear Models | 1 | 2009 | 5876 | 0.010 |
Why?
|
| Protein Precursors | 1 | 2003 | 1135 | 0.010 |
Why?
|
| Doxycycline | 1 | 2000 | 337 | 0.010 |
Why?
|
| Lymphokines | 1 | 2002 | 929 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2010 | 3107 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2001 | 368 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 2000 | 446 | 0.010 |
Why?
|
| Lasers | 1 | 2002 | 952 | 0.010 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2000 | 167 | 0.010 |
Why?
|
| Antistreptolysin | 1 | 1997 | 6 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2000 | 1061 | 0.010 |
Why?
|
| Sphenoid Bone | 1 | 1999 | 177 | 0.010 |
Why?
|
| Diffusion | 1 | 2000 | 814 | 0.010 |
Why?
|
| Leg Dermatoses | 1 | 1997 | 20 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2000 | 459 | 0.010 |
Why?
|
| Cadherins | 1 | 2002 | 898 | 0.010 |
Why?
|
| Homeostasis | 1 | 2008 | 3305 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1997 | 317 | 0.010 |
Why?
|
| Hypopituitarism | 1 | 1999 | 248 | 0.010 |
Why?
|
| Facial Dermatoses | 1 | 1997 | 85 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1997 | 383 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 2192 | 0.010 |
Why?
|
| Blood Sedimentation | 1 | 1997 | 234 | 0.010 |
Why?
|
| Biological Transport | 1 | 2000 | 2087 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 1996 | 182 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 1997 | 344 | 0.010 |
Why?
|
| Dermatitis | 1 | 1997 | 200 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 5248 | 0.010 |
Why?
|
| Cell Separation | 1 | 2000 | 1720 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1998 | 376 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1996 | 553 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2008 | 3960 | 0.010 |
Why?
|
| Arm | 1 | 1997 | 583 | 0.010 |
Why?
|
| Thorax | 1 | 1997 | 553 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2001 | 978 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2005 | 5498 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 1996 | 437 | 0.010 |
Why?
|
| Swine, Miniature | 1 | 1996 | 959 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 6378 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2000 | 1828 | 0.010 |
Why?
|
| Registries | 1 | 2009 | 8449 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 2000 | 1381 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2002 | 2874 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1996 | 1600 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 1996 | 1578 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 20048 | 0.000 |
Why?
|
| Neurosurgical Procedures | 1 | 1999 | 2056 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2009 | 24086 | 0.000 |
Why?
|
| Recurrence | 1 | 2000 | 8487 | 0.000 |
Why?
|
| Patient Selection | 1 | 1999 | 4276 | 0.000 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1997 | 1628 | 0.000 |
Why?
|
| Heart Failure | 1 | 2010 | 11835 | 0.000 |
Why?
|
| Swine | 1 | 1996 | 5902 | 0.000 |
Why?
|
| Heart Ventricles | 1 | 1996 | 3811 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2000 | 7400 | 0.000 |
Why?
|
| Infant | 1 | 1997 | 36030 | 0.000 |
Why?
|